An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic, immune-mediated ...

Please provide your email address to receive an email when new articles are posted on . Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune ...

Researchers have used various definitions to estimate the incidence and prevalence of immune thrombocytopenia (ITP) yet haven’t corroborated available data with large, population-based, multinational ...

Immune thrombocytopenia (ITP) is an autoimmune disorder characterised by both antibody-mediated platelet destruction and impaired megakaryocyte function. This results in decreased platelet counts and ...

Please provide your email address to receive an email when new articles are posted on . Eltrombopag increased durable platelet response for children with newly diagnosed immune thrombocytopenia.

Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential ...

"…consider using thrombopoietin receptor agonists as first-line therapy for new or relapsed acute ITP during the COVID-19 pandemic in patients who are negative for ...

Sanofi SNY announced that the FDA has approved Wayrilz (rilzabrutinib), a novel BTK inhibitor, for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adult patients who have had ...

The National Institute for Health and Care Excellence (NICE) has issued draft final guidance in England and Wales recommending the use of avatrombopag (Doptelet, Sobi) in adults with primary chronic ...